Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects
Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects
复制标题
DOI：
10.2337/diacare.19.6.667
复制
发表时间：
1996-06-01
期刊：
影响因子：
16.2
通讯作者：
Meier, AH
中科院分区：
文献类型：
--
作者：
Cincotta, AH;Meier, AH
目的--一项双盲安慰剂对照研究调查了麦角西（一种新型溴隐亭快速释放制剂）对体重、体脂研究设计和方法-肥胖个体（男性>25%的体脂和女性>30%的体脂）被指示遵循热量限制饮食（基于研究入组体重维持70%的体重），并随机接受Ergoset每日治疗（1.6-2.4 mg/天）或安慰剂，在18周的治疗期内于0800给药。在开始治疗前和治疗结束时对受试者进行口服葡萄糖耐量试验。结果-与安慰剂相比，麦角组治疗18周显著降低了体重和体脂肪（分别为6.3 +/-1.5和5.4 +/-1.1kg vs. 0. 9 +/-1.0和1.5 +/-0.6kg，P < 0.01）。Ergoset，而不是安慰剂，也改善了葡萄糖耐量（P < 0.02）;口服葡萄糖耐量曲线下的刺激面积减少了46%（从121 +/- 23到64 +/- 32 mg）。h（-1）。dl（-1）），而胰岛素曲线下刺激面积减少了30%。结论--在18周的治疗期内，Ergoset（而非安慰剂）与遵循适度低热量饮食的指导相结合，可改善肥胖受试者的葡萄糖耐量，并促进体重和体脂的显著减轻。
OBJECTIVE - A double-blind placebo controlled study investigated long-term effects oi Ergoset, anew quick release formulation of bromocriptine, on body weight, body fat, and glucose tolerance in a group (n = 17) of obese subjects who were instructed to follow a moderate hypocaloric diet.RESEARCH DESIGN AND METHODS - Obese individuals (>25% body fat for men and >30% body fat for women) were instructed to follow a calorie-restricted diet (70% of weight maintaining based on study entry weight) and were randomized to daily treatment with Ergoset (1.6-2.4 mg/day) or placebo at 0800 over an 18-week treatment period. Oral glucose tolerance tests were performed on subjects before initiation and again at termination oi treatment. Body weight and body fat (determined by skinfold measurements) were quantified every 2 weeks during the course oi treatment.RESULTS - Ergoset treatment for 18 weeks significantly reduced body weight and body far versus placebo (6.3 +/- 1.5 and 5.4 +/- 1.1 kg vs. 0.9 +/- 1.0 and 1.5 +/- 0.6 kg, respectively, P < 0.01). Ergoset, but not placebo, also improved glucose tolerance (P < 0.02); the stimulated area under the oral glucose tolerance curve was reduced by 46% (from 121 +/- 23 to 64 +/- 32 mg . h(-1). dl(-1)), while the stimulated area under the insulin curve was reduced by 30%.CONCLUSIONS - When combined with instruction to follow a moderate hypocaloric diet, Ergoset, but not placebo, improves glucose tolerance and promotes significant weight and body fat loss in obese subjects over an 18-week treatment period.